CoMET: a protocol for a randomised controlled trial of co-commencement of METformin as an adjunctive treatment to attenuate weight gain and metabolic syndrome in patients with schizophrenia newly commenced on clozapine

INTRODUCTION: Clozapine, while effective in treatment refractory schizophrenia, is associated with significant weight gain, heart disease and increased risk of type 2 diabetes mellitus (T2DM). Although there is evidence for weight loss with metformin for people with obesity who are already taking cl...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMJ Open
Autors principals: Siskind, Dan, Friend, Nadia, Russell, Anthony, McGrath, John J, Lim, Carmen, Patterson, Sue, Flaws, Dylan, Stedman, Terry, Moudgil, Vikas, Sardinha, Savio, Suetani, Shuichi, Kisely, Steve, Winckel, Karl, Baker, Andrea
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2018
Matèries:
Mental Health
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5855211/
https://ncbi.nlm.nih.gov/pubmed/29500217
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2017-021000
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars